{"id":"W4405374502","doi":"10.1016/j.iotech.2024.101027","title":"LBA3 Perioperative pembrolizumab (pembro) plus neoadjuvant chemotherapy (chemo) in early-stage non-small-cell lung cancer (NSCLC): A 4-year update of KEYNOTE-671","year":2024,"lang":"en","type":"article","venue":"Immuno-Oncology Technology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":6,"is_retracted":false,"has_abstract":false,"ca_institutions":"McGill University","funders":"Chugai Pharmaceutical; EMD Serono; Berlin Institute of Health; Sun Pharma; Teijin Pharma; Medizinische Universität Innsbruck; Freie Universität Berlin; Hôpitaux Universitaires de Genève; Humboldt-Universität zu Berlin; Astellas Pharma; Eisai; Daiichi-Sankyo; Sanofi; Sungkyunkwan University; BeiGene; Mirati Therapeutics; University of Queensland; Helsinn; Les Laboratories Pierre Fabre; AstraZeneca; Novocure; Pfizer; Incyte; Universität Innsbruck; Merck KGaA; Taiho Pharmaceutical; Revolution Medicines; Regeneron Pharmaceuticals; Japan Surgical Society; Yuhan; Daiichi Sankyo Europe; National Cancer Institute; Gilead Sciences; Amgen; Celgene; Eli Lilly and Company; Samsung; Bristol-Myers Squibb","keywords":"Pembrolizumab; Medicine; Oncology; Stage (stratigraphy); Perioperative; Chemotherapy; Lung cancer; Internal medicine; Cancer; Radiology; Immunotherapy; Biology","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0004759711,0.000584134,0.001404806,0.001256375,0.0001135984,0.00003782164,0.0006123501,0.001284007,0.001206479],"category_scores_gemma":[0.00003944309,0.0005255289,0.0003409308,0.0016453,0.0009833997,0.0001506948,0.0002211781,0.001289368,0.00005802807],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.001795996,"about_ca_system_score_gemma":0.002252915,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001725722,"about_ca_topic_score_gemma":0.0006275121,"domain_scores_codex":[0.9966955,0.0001149427,0.001058741,0.0009381128,0.0002621849,0.0009305739],"domain_scores_gemma":[0.9983726,0.0001275614,0.0002781515,0.0009291123,0.0002011029,0.00009143542],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","study_design_scores_codex":[0.01550478,0.0007516054,0.01837312,0.000862967,0.001473871,0.001027841,0.007360711,0.00003523428,0.8715518,0.0009370385,0.001689555,0.08043148],"study_design_scores_gemma":[0.06894076,0.006397613,0.02492078,0.002640096,0.0006727506,0.0007967437,0.005767145,0.005272923,0.6718852,0.0002252823,0.2106531,0.001827624],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9538506,0.03138736,0.0003714415,0.007449036,0.0009803334,0.001642549,0.00007230524,0.0003907369,0.003855617],"genre_scores_gemma":[0.9826371,0.01058496,0.001409112,0.0009315917,0.0001248393,0.0005689145,0.0000335995,0.0001402254,0.003569669],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.2089635,"threshold_uncertainty_score":0.9997196,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.008401937325614091,"score_gpt":0.2975276717874244,"score_spread":0.2891257344618103,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}